A survey of 1,000 Crohn’s disease (CD) patients (on behalf of the Crohn’s & Colitis Foundation of America [CCFA] and the Digestive Disease National Coalition [DDNC]) revealed that1:
Only PROMETHEUS IBD sgi Diagnostic combines serologic, genetic, and inflammatory markers to help differentiate IBD vs non-IBD and CD from UC (see Figure 1).
The incorporation of three classes of biomarkers
significantly improves the diagnostic accuracy of
PROMETHEUS IBD sgi Diagnostic, compared with
ASCA and ANCA testing.2
Out of every 100 patients tested,
PROMETHEUS IBD sgi Diagnostic correctly
indentifies 87 patients while ASCA and ANCA
only identify 64 and 65 patients, respectively
(see Figure 2).2
Multiple studies have demonstrated that specific serologic markers are associated with certain disease behavior
(see Table 1).3-7
Other studies have shown that the presence and magnitude of immune responses may influence certain disease behavior (see Figures 3-5).6,8
Your interpretation of the results from PROMETHEUS IBD sgi Diagnostic may be valuable when you are developing a patient’s prognostic risk assessment.